Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 8 of 16
Archive
Proactive news snapshot: ImmuPharma, Eurasia Mining, Tower Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
ImmuPharma says managed access programme for Lupozor progressing as planned
The AIM-listed firm said that following analysis of the regulatory processes in EU countries, it is planned to begin patient recruitment for the programme in France and UK
Archive
Proactive news snapshot: Tower Resources, MySQUAR, Kore Potash …
A glance at some of the day's highlights from the Proactive Investors newswire
Sure Ventures pleased with progress of tech investments this year
“We are especially pleased with the successful IPO of our first direct investment, Immotion PLC, that came to fruition just a short few months after cash deployment”
Archive
Proactive news snapshot: Amryt Pharma, Directa Plus, Live Company...
A glance at some of the day's highlights from the Proactive Investors newswire
ImmuPharma boss excited by “blockbuster potential” of Lupuzor
The lupus treatment missed its primary endpoint in a phase III study earlier this year, but ImmuPharma CEO Tim McCarthy still has high hopes for the drug
Managed access programmes offer an alternative way forward for drug companies
Eighteen of the top 20 big pharmaceutical companies now provide early access to their drugs
Archive
Proactive news snapshot: Pan African Resources, Strategic Minerals, Strategic Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Mission Marketing Group shares step up, United Carpets declines
A look at some of the biggest risers and fallers in the UK market on Wednesday
Investments and investor services
FTSE 100 closes higher as trade fears ebb; Kingfisher leads the laggards
The FTSE 100 closed nearly 31 points higher at 7,331, while FTSE 250 added over 42 at 20,500
Archive
Proactive news snapshot: Echo Energy, Pan African Resources, Chagala Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Airlines under pressure after IAG's British Airways unit hit by data theft
A look at some of the biggest risers and fallers in the London market on Friday
ImmuPharma’s flagship lupus drug to be made available to patients ahead of regulatory filing
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
FTSE 100 takes a dive again; miners bear brunt
FTSE 100 finished down around 41 points or 0.56%, at 7,277 as its poor run continues
EQTEC surges on new €22mln contract win
Some of the main news-driven risers and fallers in London on Thursday afternoon...
Archive
Proactive news snapshot: UK Oil & Gas Investments, ValiRx, Kazera Global …
A glance at some of the day's highlights from the Proactive Investors newswire
ImmuPharma says pre-clinical study points to other indications for lead drug
Currently being developed to treat lupus, peptide P140 may hold the potential to treat another painful autoimmune disease